Bayer Signs Grant Agreement to Advance Research in Non-Hormonal Contraception

Non-Hormonal Contraception
Bayer Signs Grant Agreement to Advance Research in Non-Hormonal Contraception :

Today, Bayer disclosed that the Bill & Melinda Gates Foundation had awarded it a grant. In order to co-fund pre-clinical research projects as part of the grant, Bayer and the Bill & Melinda Gates Foundation each pledged more than US $12 million over the course of four years. The objective was to give women all over the world a non-hormonal contraceptive choice. In addition to providing co-funding for the research over a four-year period, Bayer will use its knowledge of women’s healthcare as well as its research and development skills to find a candidate for pre-clinical development. In addition, Bayer has promised to make such a product affordable and accessible in low- and lower-middle-income nations after it has received regulatory approval.

“The collaboration brings together Bayer’s research expertise, with the Bill & Melinda Gates Foundation’s purpose, to help reduce inequalities around the world by facilitating access to health in low- and lower-middle-income countries”, “Together, we aim to further advance our vision to provide non-hormonal contraceptive options to millions of girls and women around the globe in a sustainable manner.”

Marianne De Backer, EVP, Head of Strategy, Member of the Executive Committee, Bayer Pharmaceutical


“Sustainability is an integral part of our business”, “With our strong heritage and deeply rooted expertise in women’s healthcare, Bayer has been supporting initiatives that contribute to providing women in low- and lower-middle-income countries with access to family planning for more than 50 years. We are proud to work together with the Bill & Melinda Gates Foundation and join efforts to expand access to contraceptive options that help address the unmet needs of women worldwide.”

Jeanne Kehren,

This new agreement strengthens Bayer’s dedication to offering sustainable, scientific solutions to meet the unique health needs of women everywhere and to assist in granting access to modern contraception to women and girls in low- and lower-middle-income countries (LMICs). Along with working together on The Challenge Initiative, it is the second cooperative activity in family planning that involves both parties (TCI).

Gender inequality still exists today, and adolescent pregnancies and maternal deaths continue to be major public health issues, particularly in LMICs. Modern contraceptive methods offer more options, which gives women more control over the timing of their pregnancies. In addition to being essential to women’s health, family planning may also give them more control over their life, which may have a good knock-on effect for families and communities.

Bayer, a pioneer in women’s healthcare, has supported family planning initiatives in more than 130 nations. Bayer wants to increase access to modern contraception for women around the world by working with international organisations including the United Nations Population Fund and the United States Agency for International Development. These initiatives support the United Nations’ Sustainable Development Goals.

Concerning Bayer’s Women’s Healthcare

Bayer is a well-known industry leader in women’s healthcare and has a long-standing dedication to advancing a variety of therapies while offering technology for a better life. Bayer provides a variety of efficient short- and long-acting birth control options, as well as treatments for controlling menopause symptoms. The unmet medical needs of women around the world are another area of attention for Bayer. Currently, Bayer’s research and development efforts are concentrated on developing new menopausal treatments, and this includes a number of substances that are at various stages of pre-clinical and clinical development.

Together, these initiatives represent the company’s research strategy, which emphasises targets and pathways that could change the way gynaecological disorders are handled. In addition, Bayer wants to make family planning accessible to 100 million women in low- and middle-income nations by 2030 by supporting multi-stakeholder aid initiatives and assuring the availability of reasonably priced modern contraceptives. This is in accordance with the Sustainable Development Goals of the United Nations and a component of the overall sustainability measures and commitments starting in 2020.

Next Post

Indivior To Acquire Opiant Pharmaceuticals

According to a definitive agreement between Indivior PLC and Opiant Pharmaceuticals, Inc., which the two companies announced today, Indivior will buy Opiant for an upfront payment of $20.00 per share in cash (roughly $145 million total), plus up to $8.00 per share in contingent value rights (“CVRs”) that could become […]